CDC Report Underscores Impact of Early Diagnosis and Innovation on Cancer Survival
Two out of three people with metastatic disease survive 5 years or more, the report shows. The authors hope the data can help researchers develop better cancer control programs.
Geography Determines Appropriate Use of Imaging in Low-Risk Cancer Patients
The study, published in JAMA Oncology, found that low risk breast and prostate cancer patients received unnecessary imaging overall, with a higher rate observed in the North East region of the country.
ACS Study Recommends Increased Screening to Reduce Incidence of Colorectal Cancer
The study, published in the journal Cancer found that increasing screening rates to 80% by 2018 would reduce projected colorectal cancer incidence rates by 17% and mortality rates by 19% during short-term follow-up, and by 22% and 33%, respectively, during extended follow-up. Those reductions would amount to a total of 277,000 averted new cancers and 203,000 averted colorectal cancer deaths from 2013 through 2030.
A New Strategy for Payers to Cover High Cost Specialty Medications?
A new analysis published by the RAND Corporation suggests strategies that the pharmaceutical industry could offer payers as they try to cover the front-loaded cost of newer breakthrough drugs.
Secretary Burwell Reflects on Open Enrollment and Looks Ahead
Although HHS Secretary Sylvia M. Burwell touted the success of this past open enrollment period and the affordability of quality health plans, she declined to comment on King v. Burwell during her keynote speech at America’s Health Insurance Plans (AHIP)’s National Health Policy Conference.
Dietary Restrictions Could Prevent Colon Cancer
The study, published in JAMA Internal Medicine, found that while the complete absence of meat in the diet had the most impact on reducing the risk of colorectal cancer, those who added seafood to the vegetarian diet—pescovegetarians—faired better than the nonvegetarians.
Study Shows Experienced Care Facilities Improve Survival in NSCLC
The study, published in the Journal of Thoracic Oncology, found that patients treated with definitive concurrent chemotherapy and radiation therapy for stage 3 non-small cell lung cancer have longer overall survival when treated by highly experienced facilities, either academic or community cancer centers.
Novel Strategy Determines Cost of Prostate Condition Treatments
A novel costing strategy has been used to determine the cost of care across the entire care process for benign prostate hyperplasia, according to researchers from the University of California, Los Angeles.
Myriad's Gene Panel Could Diagnose Metastatic Melanoma
The 23-gene diagnostic panel called myPath Melanoma could be used in addition to microscopy to distinguish the benign form of the disease from malignant disease.
Can Congress Fix Healthcare Reform if SCOTUS Removes Federal Subsidies?
A discussion on the Supreme Court oral arguments for King v. Burwell got very heated as America’s Health Insurance Plans kicked off its National Health Policy Conference in Washington, DC, on March 11.
Scientist Whose Discoveries Helped Develop Ipilimumab Among ASCO Honorees
The awards will be presented at ASCO's annual meeting to be held in Chicago in May this year.
Medicaid Expansion Not Happening in Montana
Obamacare’s tenuous toehold in Montana appears to be growing no firmer. Despite a hearing crowded with supporters of the Democratic governor’s Medicaid expansion bill, Republican legislators have dealt the measure a likely death blow.
NCQA President Reflects on Challenges Ahead in Ensuring That Quality Takes Center Stage in Patient Care
As The American Journal of Managed Care marks its 20th year of publication, the editors invited Margaret O’Kane, the founding and current president of the National Committee on Quality Assurance, to address today’s retail environment for healthcare consumers. In 2015, NCQA marks its 25th year of improving healthcare quality through measurement, transparency, and accountability.
NICE Recommends Gazyvaro for Treatment-Naive CLL Patients
The recommendation has not come easy for Roche. Back in October 2014, NICE had rejected Gazyravo based on inconsistencies in the filing, which were then addressed by the drug manufacturer. Subsequently, NICE struck a deal with Roche to provide the drug to NHS at a reduced price.
New CMS ACO Model Takes on More Risk With Potentially Greater Rewards
CMS announced the Next Generation Accountable Care Organization Model, which takes on greater performance risk but could potentially reap greater rewards.
ACA Causes Modest Change in ED Use Among Young Adults
Young adults appear to have changed their use of the emergency department since the implementation of the Affordable Care Act to reflect a more efficient use of medical care, according to a new report in the Annals of Emergency Medicine.
Amgen Plans for Up to 5 Biosimilars by 2019
At a state-of-the-art facility in Thousand Oaks, California, drugmaker Amgen Inc. is perfecting the art of copying others, and it must work fast because copycats are already coming for Amgen's drugs.
Breast Cancer Survivors Have Increased Risk of Thyroid Cancer
Within 5 years of a breast cancer diagnosis, patients are at an increased risk of developing thyroid cancer, according to a new study, which was presented at the Endocrine Society’s 97th annual meeting.
Access to Medical Records Eases Patients Worry in Hospital
Letting patients see their medical records while they’re in the hospital might ease worry and confusion without extra work for doctors and nurses, a small study suggests.
Study Evaluates Benefits of Cap on Prescription Drug Cost-Sharing for Patients on Exchanges
Commissioned by The Leukemia and Lymphoma Society, the results of the study help make the case for placing limits on out-of-pocket costs for patients that would relieve their financial burden without a significant impact to insurers.
Drug Spending Largely Driven by HCV Drugs, Compounded Medications
Just 2 therapy classes are responsible for more than half of the increase in overall prescription drug spending in the United States, reported Express Scripts.
Escalating Drug Prices Not a Concern for All
While the PBM Express Scripts declared plans to bring cancer drug plans down, the drug manufacturers and investors aren't too worried about the high cost of some of the specialty drugs, according to this article in Bloomberg.
Oregon Officially Kills Its Insurance Exchange
Oregon Gov Kate Brown signed a bill shutting down the troubled, and expensive, state health insurance exchange, Cover Oregon.
Prostate Cancer in the Family Tree Increases A Woman's Risk of Breast Cancer
A study, published in the journal Cancer, found that women with a family history of both breast and prostate cancer among first-degree relatives have an almost 2-fold increase in risk of developing breast cancer themselves.
ASCO and PhRMA Critical of the CMS Oncology Care Model
One of the criticisms, which came from ASCO, points to the absence of consideration for patient heterogeneity that can result in physicians being penalized for providing patient-centered treatment.